#
Vimpat Intravenous
  • Drugs A to Z
  • Vimpat (Intravenous)

Vimpat (Intravenous)

Generic name:lacosamide (intravenous route) [ la-KOE-sa-mide ]
Drug class:Miscellaneous anticonvulsants

Medically reviewed by Drugs.com. Last updated on May 9, 2022.

Commonly used brand name(s)

In the U.S.

  • Vimpat

Available Dosage Forms:

  • Solution

Therapeutic Class: Anticonvulsant

Uses for Vimpat

Lacosamide injection is used to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures. It acts on the central nervous system (CNS) to reduce the number and severity of seizures.

This medicine is to be given only by or under the direct supervision of your doctor.

Before using Vimpat

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of lacosamide injection in children younger than 4 years of age to treat primary generalized tonic-clonic seizures and in children younger than 1 month of age to treat partial-onset seizures. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of lacosamide injection in the elderly. However, elderly patients are more likely to have age-related liver, kidney, or heart problems, which may require caution and an adjustment in the dose for patients receiving lacosamide injection.

Breastfeeding

There are no adequate studies in women for determ...